Effects and Mechanisms of Nutrition Management and Antihypertensive drug administration for Nonalcoholic Steatohepatitis

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K20197
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Kobe Shoin Women's University
• Principal Investigator: Hashimoto Sayuki 神戸松蔭女子学院大学, 人間科学部, 講師 (90707530)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 非アルコール性脂肪性肝炎 / 繊維化 / 降圧剤投与 / 食事療法 / SHRSP5/Dmcr

Outline of Final Research Achievements

Pathological evaluation showed smaller fat droplets in the central venous region in the valsartan group and sinusoids in the hydralazine group, with cells recovered from the central venous region. In the portal vein area, the valsartan group showed more normal cells, while the hydralazine group showed more fat droplets. Lipid staining showed large fat droplets in areas of less dense fibrosis in the control group, while areas of dense fibrosis did not recover. In the valsartan group, lipid was reduced overall, but remained near the central vein, while in the hydralazine group, lipid was reduced only near the central vein. The results, including Western blot results, suggest that valsartan is more effective in reducing lipids, while hydralazine is more effective in improving fibrosis.

Free Research Field

栄養学および健康科学関連

Academic Significance and Societal Importance of the Research Achievements

これまでNASHの治療は脂質とコレステロールの摂取制限を主体とした栄養管理が第一選択であったが、栄養管理だけでは肝臓の繊維化の軽減や完全な改善は困難であった。動物モデルを用いた研究より高血圧がNASH進展に関わっている可能性があるということから、NASHの予防・治療に降圧剤の投与を選択するという新たな視点を与えることが出来る。